CCT137690 is primarily utilized in research settings as a potent and selective inhibitor of Aurora kinases, particularly Aurora A and Aurora B. These kinases play crucial roles in cell division and are often overexpressed in various cancers. By inhibiting these kinases, CCT137690 disrupts mitotic processes, leading to cell cycle arrest and apoptosis in cancer cells. This makes it a valuable tool for studying the mechanisms of mitosis and exploring potential therapeutic strategies for cancer treatment. Additionally, its application extends to understanding the role of Aurora kinases in other cellular processes, such as chromosomal stability and spindle assembly. Researchers also use CCT137690 to investigate its effects in combination with other anticancer agents, aiming to enhance therapeutic efficacy and overcome drug resistance in preclinical models.